182 related articles for article (PubMed ID: 20060241)
1. Imaging and biomarkers for Alzheimer's disease.
Allan CL; Sexton CE; Welchew D; Ebmeier KP
Maturitas; 2010 Feb; 65(2):138-42. PubMed ID: 20060241
[TBL] [Abstract][Full Text] [Related]
2. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
3. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
Andreasen N; Blennow K
Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
Schmand B; Huizenga HM; van Gool WA
Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease.
Mosconi L; De Santi S; Rusinek H; Convit A; de Leon MJ
Expert Rev Neurother; 2004 Sep; 4(5):831-49. PubMed ID: 15853510
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease.
Kantarci K
Expert Rev Neurother; 2005 Sep; 5(5):663-70. PubMed ID: 16162090
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
8. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
9. [The progress of Alzheimer's disease research biomarkers--sensitivity and specificity].
Shoji M
Rinsho Shinkeigaku; 2000 Dec; 40(12):1234-6. PubMed ID: 11464465
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
12. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosing the mild cognitive impairment stage of Alzheimer's disease].
Maruyama M; Matsui T; Tanji H; Ootsuki M; Nemoto M; Tomita N; Okamura N; Matsushita S; Higuchi S; Kodama M; Arai H; Sasaki H
Seishin Shinkeigaku Zasshi; 2004; 106(3):269-80. PubMed ID: 15164576
[TBL] [Abstract][Full Text] [Related]
14. [Use of CSF biomarkers in the diagnostics of memory diseases].
Remes A; Leikola M; Majamaa K; Nikkanen M; Ruokonen LI; Rusanen M; Tapiola T; Ylikotila P; Vallittu AM; Pirttilä T
Duodecim; 2009; 125(20):2215-22. PubMed ID: 19998760
[TBL] [Abstract][Full Text] [Related]
15. [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].
Förstl H; Werheid K; Ulm K; Schönknecht P; Schmidt R; Pantel J; Hörr R; Gutzmann H; Gertz HJ; Frölich L; Bickel H
Dtsch Med Wochenschr; 2009 Jan; 134(3):88-91. PubMed ID: 19142839
[TBL] [Abstract][Full Text] [Related]
16. CSF biomarkers for mild cognitive impairment.
Blennow K
J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
[TBL] [Abstract][Full Text] [Related]
17. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for Alzheimer's disease.
Sonnen JA; Keene CD; Montine KS; Li G; Peskind ER; Zhang J; Montine TJ
Expert Rev Neurother; 2007 Aug; 7(8):1021-8. PubMed ID: 17678497
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
20. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
